Abstract
Mitochondria are membrane-enclosed organelle found in most eukaryotic cells, where they generate the majority of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition, they are involved in a range of other processes, such as signalling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Mitochondria have been implicated in several neuropsychiatric disorders, in particular, depression, anxiety, schizophrenia, autism, and Alzheimer's dementia. Furthermore, the presence of mutations at the level of mitochondrial or nuclear DNA (mtDNA and nDNA, respectively) has been linked to personality disorders, behavioral disturbances, thought alterations, impulsivity, learning impairment, cognitive failures until dementia. The aim of this paper is to review the literature on the relationship between psychiatric symptoms or syndromes and mtDNA mutations or mitochondrial alterations, while highlighting novel therapeutic targets for a broad range of disorders.
Keywords: Mitochondria, ATP, Genetics, Mitochondrial Diseases, Schizophrenia, Mood Disorders, Anxiety Disorders, Autism, ADHD, Alzheimer's disease
Current Medicinal Chemistry
Title: Mitochondrial Alterations and Neuropsychiatric Disorders
Volume: 18 Issue: 30
Author(s): D. Marazziti, S. Baroni, M. Picchetti, P. Landi, S. Silvestri, E. Vatteroni and M. Catena Dell'Osso
Affiliation:
Keywords: Mitochondria, ATP, Genetics, Mitochondrial Diseases, Schizophrenia, Mood Disorders, Anxiety Disorders, Autism, ADHD, Alzheimer's disease
Abstract: Mitochondria are membrane-enclosed organelle found in most eukaryotic cells, where they generate the majority of the cell's supply of adenosine triphosphate (ATP), used as a source of chemical energy. In addition, they are involved in a range of other processes, such as signalling, cellular differentiation, cell death, as well as the control of the cell cycle and cell growth. Mitochondria have been implicated in several neuropsychiatric disorders, in particular, depression, anxiety, schizophrenia, autism, and Alzheimer's dementia. Furthermore, the presence of mutations at the level of mitochondrial or nuclear DNA (mtDNA and nDNA, respectively) has been linked to personality disorders, behavioral disturbances, thought alterations, impulsivity, learning impairment, cognitive failures until dementia. The aim of this paper is to review the literature on the relationship between psychiatric symptoms or syndromes and mtDNA mutations or mitochondrial alterations, while highlighting novel therapeutic targets for a broad range of disorders.
Export Options
About this article
Cite this article as:
Marazziti D., Baroni S., Picchetti M., Landi P., Silvestri S., Vatteroni E. and Catena Dell'Osso M., Mitochondrial Alterations and Neuropsychiatric Disorders, Current Medicinal Chemistry 2011; 18(30) . https://dx.doi.org/10.2174/092986711797379221
DOI https://dx.doi.org/10.2174/092986711797379221 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Hydrophobic Plant Antioxidants. Preparation of Nanoparticles and their Application for Prevention of Neurodegenerative Diseases. Review and Experimental Data
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Auditory Processing Disorder (Guest Editors: Vasiliki Maria Iliadou)]
Current Pediatric Reviews Glycogen Synthase Kinase-3: A Potential Target for Drug Discovery in the Treatment of Neurodegenerative Disorders
Current Enzyme Inhibition Recent Approaches to Novel Anti-Alzheimer Therapy
Current Pharmaceutical Design Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Review of Bioinformatics and Theoretical Studies of Acetylcholinesterase Inhibitors
Current Bioinformatics Editorial [Hot Topic New Clinical Indications of Antipsychotic Medications Guest Editors: Filippo Bogetto and Silvio Bellino]
Current Psychopharmacology The Role of Inflammatory Biomarkers in the Detection and Therapy of Atherosclerotic Disease
Current Vascular Pharmacology Evidence Based Psychosocial Practices and Recovery from Schizophrenia
Current Psychiatry Reviews Phytochemicals for Drug Discovery in Alzheimer’s Disease: <i>In Silico</i> Advances
Current Pharmaceutical Design Studies on the Transdermal Delivery of Nimodipine from a Menthol-based TTS in Human Volunteers
Current Drug Delivery Channel-Like Functions of the 18-kDa Translocator Protein (TSPO): Regulation of Apoptosis and Steroidogenesis as Part of the Host-Defense Response
Current Pharmaceutical Design Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design A Decrease in the Cellular Phosphodiester to Phosphomonoester Lipid Ratio is Characteristic of HIV-1 Infection
Current HIV Research Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Synthesis and Biological Evaluation of Hexahydropyrrolo[2,3-b]Indole Derivatives as Fungicides against Phytopathogenic Fungi
Combinatorial Chemistry & High Throughput Screening Chronic Kidney Disease - Different Role for HDL?
Current Medicinal Chemistry Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents